Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 1;204(7):756-759.
doi: 10.1164/rccm.202107-1625ED.

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION

Thomas M Cascino  1 , Vallerie V McLaughlin  1
Affiliations
Editorial

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION

Thomas M Cascino et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Initial treatment strategy for pulmonary arterial hypertension. Intermediate-risk patients can be treated with an initial treatment strategy of either maximal medical therapy with triple combination therapy, including a parenteral prostacyclin, or aggressive titration with dual oral therapy. Selection of a treatment strategy requires shared decision-making. The risks, uncertainties, and potential benefits of maximal medical therapy with upfront triple combination therapy including a parenteral prostacyclin should be discussed at the time of diagnosis. There should be a plan for a rapid reassessment of response at 3 months if an aggressive titration strategy is chosen. IV = intravenous; PAH = pulmonary arterial hypertension; PCA = prostacyclin analog; SQ = subcutaneous.
See this image and copyright information in PMC

Comment on

  • Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
    Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Boucly A, et al. Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC. Am J Respir Crit Care Med. 2021. PMID: 34185620

References

    1. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291–305. - PubMed
    1. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889. - PMC - PubMed
    1. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–844. - PubMed
    1. Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204:842–854. - PubMed
    1. Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;203:484–492. - PubMed